BSNL Deploys 4G Mobile Services in Delhi Under Partner Network Access Arrangement
ByAinvest
Friday, Aug 15, 2025 4:44 am ET1min read
BNGO--
The company's CEO, Robert Erik Holmlin, attributed the positive performance to a strategic shift made in September 2024 that prioritized supporting routine users of Bionano's optical genome mapping (OGM) technology. This shift has led to a 16% increase in consumables and software revenue, which now form the bulk of recurring sales [2]. The company also reported a 17% increase in flowcell sales, with 7,233 units sold in Q2 2025 compared to 6,165 in Q2 2024 [3].
Holmlin further stated that the company's strategy shift is working, with gross margin above 50% in Q2 2025. This was achieved through a combination of higher-margin consumables and software sales, as well as internal cost reductions. Operating expenses fell sharply by 42% to $11.3 million, a significant decrease from the prior year [2].
The company's installed base of OGM systems increased to 378, a 4.1% increase from the prior year, reflecting stable demand within key customer segments. The company also reported a record 119 peer-reviewed publications, highlighting the growing utilization of OGM technology in research markets [3].
Looking ahead, Bionano Genomics has raised its 2025 OGM installation target to 20–25, up from its prior guidance of 15–20. The company expects full-year 2025 revenue to be in the range of $26.0 to $30.0 million, with Q3 2025 revenue expected to be in the range of $6.7 to $7.2 million [1]. The company's cash runway is projected to extend into Q1 2026, assuming ongoing expense controls and stable market conditions [1].
References:
[1] https://seekingalpha.com/news/4485650-bionano-genomics-reports-q2-results
[2] https://www.nasdaq.com/articles/bionano-genomics-posts-q2-margin-gain
[3] https://www.biospace.com/press-releases/bionano-reports-second-quarter-2025-results-and-highlights-recent-business-progress
Bionano Genomics has raised its 2025 OGM installation target to 25 as consumables and software revenue climbs 16%. CEO Robert Erik Holmlin described Q2 2025 as "solid," attributing the positive performance to a strategic shift made in September 2024 that prioritized supporting routine users of Bionano's optical genome mapping technology.
Bionano Genomics, Inc. (NASDAQ: BNGO) reported its Q2 2025 financial results on August 14, 2025, showcasing a strategic shift that is beginning to yield positive results. The company reported a net loss of $6.86 million, a 13.4% year-over-year (Y/Y) decrease in revenue to $6.73 million, which exceeded analyst estimates by $0.17 million [1]. However, the company's gross margin expanded to 52%, up from 35% in Q2 2024, indicating a significant improvement in operational efficiency [2].The company's CEO, Robert Erik Holmlin, attributed the positive performance to a strategic shift made in September 2024 that prioritized supporting routine users of Bionano's optical genome mapping (OGM) technology. This shift has led to a 16% increase in consumables and software revenue, which now form the bulk of recurring sales [2]. The company also reported a 17% increase in flowcell sales, with 7,233 units sold in Q2 2025 compared to 6,165 in Q2 2024 [3].
Holmlin further stated that the company's strategy shift is working, with gross margin above 50% in Q2 2025. This was achieved through a combination of higher-margin consumables and software sales, as well as internal cost reductions. Operating expenses fell sharply by 42% to $11.3 million, a significant decrease from the prior year [2].
The company's installed base of OGM systems increased to 378, a 4.1% increase from the prior year, reflecting stable demand within key customer segments. The company also reported a record 119 peer-reviewed publications, highlighting the growing utilization of OGM technology in research markets [3].
Looking ahead, Bionano Genomics has raised its 2025 OGM installation target to 20–25, up from its prior guidance of 15–20. The company expects full-year 2025 revenue to be in the range of $26.0 to $30.0 million, with Q3 2025 revenue expected to be in the range of $6.7 to $7.2 million [1]. The company's cash runway is projected to extend into Q1 2026, assuming ongoing expense controls and stable market conditions [1].
References:
[1] https://seekingalpha.com/news/4485650-bionano-genomics-reports-q2-results
[2] https://www.nasdaq.com/articles/bionano-genomics-posts-q2-margin-gain
[3] https://www.biospace.com/press-releases/bionano-reports-second-quarter-2025-results-and-highlights-recent-business-progress
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet